Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia. (JEWEL II)

January 26, 2021 updated by: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)

To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing the percentage of subjects who reach target blood pressure (BP) and LDL-C targets as defined by their governing guidelines.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment

1120

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

        • Pfizer Investigational Site
  • Austria
      • Salzburg, Austria, A-5020
        • Pfizer Investigational Site
      • St. Poelten, Austria, A-3100
        • Pfizer Investigational Site
      • Vienna, Austria, A-1090
        • Pfizer Investigational Site
      • Wels, Austria, A-4600
        • Pfizer Investigational Site
  • Belgium
      • Bierbeek, Belgium, 3360
        • Pfizer Investigational Site
      • Braine-L'Alleud, Belgium, 1420
        • Pfizer Investigational Site
      • Brugge, Belgium, 8000
        • Pfizer Investigational Site
      • De Pinte, Belgium, 9840
        • Pfizer Investigational Site
      • Gozée, Belgium, 6534
        • Pfizer Investigational Site
      • Seraing, Belgium, 4100
        • Pfizer Investigational Site
      • Wemmel, Belgium, 1780
        • Pfizer Investigational Site
      • Wilrijk, Belgium, 2610
        • Pfizer Investigational Site
      • Zedelgem, Belgium, 8210
        • Pfizer Investigational Site
  • Finland
      • Helsinki, Finland, 00260
        • Pfizer Investigational Site
      • Kuopio, Finland, 70100
        • Pfizer Investigational Site
      • Kuopio, Finland, 70110
        • Pfizer Investigational Site
      • Oulu, Finland, 90100
        • Pfizer Investigational Site
      • Oulu, Finland, 90150
        • Pfizer Investigational Site
      • Tampere, Finland, 33210
        • Pfizer Investigational Site
      • Turku, Finland, 20520
        • Pfizer Investigational Site
      • Turku, Finland, 20360
        • Pfizer Investigational Site
      • Vantaa, Finland, 01300
        • Pfizer Investigational Site
  • Greece
      • Athens, Greece, 11527
        • Pfizer Investigational Site
      • Ioannina, Greece, 45500
        • Pfizer Investigational Site
      • Larissa, Greece, 41110
        • Pfizer Investigational Site
      • Melissia, Greece, 15127
        • Pfizer Investigational Site
      • Pireaus, Greece, 18526
        • Pfizer Investigational Site
      • Rio, Patra, Greece, 26499
        • Pfizer Investigational Site
      • Thessaloniki, Greece
        • Pfizer Investigational Site
      • Thessaloniki, Greece, 54 639
        • Pfizer Investigational Site
    • Crete
      • Heraklion, Crete, Greece, 71 110
        • Pfizer Investigational Site
  • Hungary
      • Budapest, Hungary, 1106
        • Pfizer Investigational Site
      • Budapest, Hungary, 1115
        • Pfizer Investigational Site
      • Budapest, Hungary, 1083
        • Pfizer Investigational Site
      • Debrecen, Hungary, 4043
        • Pfizer Investigational Site
      • Kecskemét, Hungary, 6000
        • Pfizer Investigational Site
      • Miskolc, Hungary, 3526
        • Pfizer Investigational Site
      • Mosonmagyaróvár, Hungary, 9200
        • Pfizer Investigational Site
      • Pécs, Hungary, 7624
        • Pfizer Investigational Site
      • Szekszárd, Hungary, 7100
        • Pfizer Investigational Site
  • Ireland
    • Wexford
      • Gorey, Wexford, Ireland
        • Pfizer Investigational Site
      • New Ross, Wexford, Ireland
        • Pfizer Investigational Site
  • Italy
      • Asti, Italy, 14100
        • Pfizer Investigational Site
      • Bologna, Italy, 40139
        • Pfizer Investigational Site
      • Bologna, Italy, 40133
        • Pfizer Investigational Site
      • Bologna, Italy, 40126
        • Pfizer Investigational Site
      • Bolzano, Italy, 39100
        • Pfizer Investigational Site
      • Brescia, Italy, 25123
        • Pfizer Investigational Site
      • Catania, Italy, 95123
        • Pfizer Investigational Site
      • Catania, Italy, 95124
        • Pfizer Investigational Site
      • Chieti, Italy, 66013
        • Pfizer Investigational Site
      • Ferrara, Italy, 44100
        • Pfizer Investigational Site
      • Firenze, Italy, 50139
        • Pfizer Investigational Site
      • Foggia, Italy, 71100
        • Pfizer Investigational Site
      • Genova, Italy, 16132
        • Pfizer Investigational Site
      • Grosseto, Italy, 58100
        • Pfizer Investigational Site
      • Napoli, Italy, 80131
        • Pfizer Investigational Site
      • Novara, Italy, 28100
        • Pfizer Investigational Site
      • Palermo, Italy, 90127
        • Pfizer Investigational Site
      • Palermo, Italy, 90100
        • Pfizer Investigational Site
      • Perugia, Italy, 06126
        • Pfizer Investigational Site
      • Potenza, Italy, 85100
        • Pfizer Investigational Site
      • Prato, Italy, 59100
        • Pfizer Investigational Site
      • Roma, Italy, 00161
        • Pfizer Investigational Site
      • Salerno, Italy, 84100
        • Pfizer Investigational Site
      • Sassari, Italy, 07100
        • Pfizer Investigational Site
      • Siena, Italy, 53100
        • Pfizer Investigational Site
      • Torino, Italy, 10133
        • Pfizer Investigational Site
      • Venezia, Italy, 30122
        • Pfizer Investigational Site
    • (mi)
      • Vimercate, (mi), Italy, 20059
        • Pfizer Investigational Site
    • (va)
      • Somma Lombardo, (va), Italy, 21019
        • Pfizer Investigational Site
    • PG
      • San Sisto, PG, Italy, 06080
        • Pfizer Investigational Site
    • VE
      • Mestre, VE, Italy, 30175
        • Pfizer Investigational Site
  • Portugal
      • Coimbra, Portugal, 3000
        • Pfizer Investigational Site
      • Faro, Portugal, 8000
        • Pfizer Investigational Site
      • Leiria, Portugal, 2410
        • Pfizer Investigational Site
      • Lisboa, Portugal, 1300
        • Pfizer Investigational Site
      • Lisboa, Portugal, 1990-050
        • Pfizer Investigational Site
      • Lisbon, Portugal, 1169-024
        • Pfizer Investigational Site
      • Porto, Portugal, 4000
        • Pfizer Investigational Site
      • Porto, Portugal, 4050-113
        • Pfizer Investigational Site
      • S. Martinho Do Bispo, Portugal, 3040
        • Pfizer Investigational Site
      • Viana do Castelo, Portugal, 4900-858
        • Pfizer Investigational Site
    • Penafiel
      • Guilhufe - PNF, Penafiel, Portugal, 4560-162
        • Pfizer Investigational Site
    • Sra. Da Hora
      • Matosinhos, Sra. Da Hora, Portugal, 4464-513
        • Pfizer Investigational Site
  • Slovenia
      • Izola, Slovenia, 6310
        • Pfizer Investigational Site
      • Ljubljana, Slovenia, 1000
        • Pfizer Investigational Site
      • Maribor, Slovenia, 2000
        • Pfizer Investigational Site
  • Spain
      • Barcelona, Spain, 08036
        • Pfizer Investigational Site
      • Barcelona, Spain, 08025
        • Pfizer Investigational Site
      • Madrid, Spain, 28041
        • Pfizer Investigational Site
      • Madrid, Spain, 28040
        • Pfizer Investigational Site
    • Guipuzcoa
      • San Sebastian, Guipuzcoa, Spain, 20014
        • Pfizer Investigational Site
    • Tarragona
      • Reus, Tarragona, Spain, 43201
        • Pfizer Investigational Site
  • Switzerland
    • AG
      • Baden, AG, Switzerland, CH-5404
        • Pfizer Investigational Site
    • BE
      • Bern, BE, Switzerland, CH-3010
        • Pfizer Investigational Site
    • BS
      • Basel, BS, Switzerland, CH-4031
        • Pfizer Investigational Site
    • SG
      • St. Gallen, SG, Switzerland, CH-9007
        • Pfizer Investigational Site
    • TG
      • Münsterlingen, TG, Switzerland, CH-8596
        • Pfizer Investigational Site
    • TI
      • Lugano, TI, Switzerland, CH-6900
        • Pfizer Investigational Site
    • VD
      • Lausanne, VD, Switzerland, CH-1011
        • Pfizer Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines

Exclusion Criteria:

  • High liver enzymes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
To evaluate the effectiveness of amlodipine/atorvastatin therapy by assessing percentage of subjects who reach target BP and LDL-C targets as defined by their governing guidelines.

Secondary Outcome Measures

Outcome Measure
To asses changes since baseline of lab parameters, BP, safety of titration of amlodipine.atorvastatin to reach targets, to validate Expectations and Satisfaction with Treatment questionnaires.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2004

Study Completion

September 1, 2006

Study Registration Dates

First Submitted

September 9, 2005

First Submitted That Met QC Criteria

September 9, 2005

First Posted (Estimate)

September 15, 2005

Study Record Updates

Last Update Posted (Actual)

January 27, 2021

Last Update Submitted That Met QC Criteria

January 26, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A3841029

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Clinical Trials on Amlodipine/atorvastatin single pill

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe